JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement to be taken private. The firm expects a completed privatization of the company within the first half of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
- BLUE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BofA moves to No Rating on Bluebird Bio after deal announcement
- Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
- Bluebird Bio trading resumes
- Bluebird Bio trading halted, volatility trading pause
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue